Discontinue antiseizure medications

Phase 3

UUniversity of Michigan

Discontinue antiseizure medications is one of 49 therapeutic programs targeting Epilepsy. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

EpilepsyRecruiting

EpilepsyPhase 3

Recruiting

Competition

Competitive Landscape

87 competitors in Epilepsy

#DrugCompanyPhaseTrials

Tegretol

Novartis

Approved

11 2

Vimpat

UCB

Approved

11 3

Fycompa

CCatalyst Biosciences

Approved

14 4

Lexapro

AbbVie

Approved

2 5

Briviact

UCB

Phase 3

15 6

Dilantin

VViatris Specialty LLC

Approved

3 7

Zoloft

VViatris Specialty LLC

Approved

2 8

Epidiolex

Jazz Pharmaceuticals

Phase 3

9 9

Ketalar

AAultman Health Foundation

Approved

1 10

Klonopin

EEngelhard Arzneimittel GmbH & Co.KG

Approved

—

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q3 2029

ApprovedRecruiting

Epilepsy

NCT07750496

Clinical

Trials by Indication[1]

Epilepsy1 trial

Study Testing Outcomes After Planned Discontinuation of AntiSeizure Medication

Recruiting·UUniversity of Michigan·Approved·NCT07750496·40 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Discontinue antiseizure medications. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for Discontinue antiseizure medications. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — University of Michigan company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: UUniversity of Michigan

Discontinue antiseizure medications

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q3 2029

Trials by Indication[1]

Epilepsy1 trial

References

Drug Info

Quick Facts

Related News